Experimental human pneumococcal carriage in adults with HIV in Malawi

This study established a safe and acceptable experimental human pneumococcal carriage model in Malawi, revealing that while virally suppressed people living with HIV are not more susceptible to initial pneumococcal acquisition than HIV-uninfected adults, they exhibit impaired clearance, suggesting that prolonged carriage duration rather than increased susceptibility drives the high pneumococcal carriage rates observed in this population.

The Gist

The Big Picture: A "Controlled Exposure" Experiment

Imagine you want to understand why a specific type of mold grows faster and sticks around longer in some houses than others. Usually, you'd have to wait for rain and hope the mold shows up naturally, which takes a long time and is hard to control.

Instead, this study decided to spray a tiny, safe amount of that mold directly into the noses of two groups of people to see what happens. This is called a "Controlled Human Infection Model" (CHIM). It's like a scientific "test drive" to see how the body reacts to a germ in a safe, monitored environment.

The Two Groups

The researchers compared two groups of adults in Malawi:

1. Group A: People living with HIV (PLHIV) who are healthy, taking their medication, and have their virus under control.
2. Group B: People who do not have HIV.

The Goal: To see if the HIV group is more likely to "catch" the bacteria (called Streptococcus pneumoniae, or pneumococcus) and if they hold onto it longer than the non-HIV group.

The Experiment: Spraying the Germ

The scientists used a specific strain of bacteria (Serotype 6B) that is known to be safe for this kind of test. They sprayed it up the noses of 75 people from Group A and 75 people from Group B. They started with a very small amount and increased the dose for different people to find the right level to see a reaction without causing harm.

What They Found

1. Safety First (The "No Crashes" Report)
Think of this like testing a new car on a track. The most important question is: "Did anyone crash?"

• Result: No one had a serious accident. No one needed to be hospitalized.
• Side Effects: A few people in both groups felt a little sick (like a sore throat or mild cough), but the rates were almost identical between the HIV and non-HIV groups.
• Acceptability: Almost everyone (99%) said, "Yes, I would do this again," and felt the study was safe and respectful.

2. The Surprise: Who Got "Infected"?
The researchers expected that because people with HIV often have weaker immune systems, they would be much easier to "infect" with the bacteria. They thought Group A would catch it much more often.

• The Reality: The opposite happened.
  • Group B (No HIV): 36% caught the bacteria.
  • Group A (HIV): Only 21% caught the bacteria.
• The Analogy: Imagine two gardens. You throw seeds into both. You expected the garden with the weaker soil (HIV) to grow more weeds. Instead, the garden with the healthy soil (No HIV) grew more weeds. The "weak soil" garden actually caught fewer seeds.

3. The "Why" Behind the Surprise
Why did the HIV group catch it less?

• The Antibiotic Shield: Many people with HIV in Malawi take a daily antibiotic called cotrimoxazole to prevent infections. The study found that those who were actually taking this medicine (detected in their blood) rarely caught the bacteria. It acted like a shield.
• The Selection Bias: The people in the study were very healthy and disciplined (they had been on HIV meds for years and were very stable). They might be more health-conscious than the average person with HIV in the community, which could explain why they didn't catch the germ as easily as expected.

4. The Real Problem: Holding On
While the HIV group was less likely to catch the germ initially, once they did catch it, they had a harder time getting rid of it.

• The Analogy: Imagine two people who both pick up a sticky piece of gum.
  • The non-HIV person shakes their hand and the gum falls off quickly.
  • The HIV person shakes their hand, but the gum sticks to their fingers for much longer.
• The Data: The bacteria stayed in the noses of the HIV group for a longer time. This suggests that the high rates of infection seen in the real world aren't because HIV people catch it more often, but because they can't clear it fast enough.

The Bottom Line

This study established a new, safe way to test how HIV affects the body's battle against pneumococcus.

The main takeaway is a twist on what we thought we knew:

• Myth: People with HIV catch this bacteria more easily because their immune systems are weak.
• Reality (in this study): They didn't catch it more easily (perhaps because of their medication or health habits).
• The Real Issue: When they do catch it, their bodies struggle to flush it out, leading to a longer "stay" of the bacteria.

This helps scientists understand that to fix the problem in the community, we might need to focus on helping the body clear the bacteria faster, rather than just trying to stop people from catching it in the first place.

Technical Summary

Technical Summary: Experimental Human Pneumococcal Carriage in People Living with HIV in Malawi

Problem Statement
People living with HIV (PLHIV) in sub-Saharan Africa face a disproportionately high burden of pneumococcal disease and carriage compared to HIV-uninfected adults, even when virally suppressed on antiretroviral therapy (ART). In Malawi, PLHIV exhibit higher rates, density, and duration of pneumococcal carriage, contributing to a high force of infection that challenges vaccine-induced herd immunity and drives antimicrobial resistance. Despite this burden, there is no established vaccination strategy specifically targeting pneumococcal carriage in adult PLHIV in the region. Previous vaccine trials have yielded mixed results, with the pneumococcal polysaccharide vaccine (PPV23) associated with excess disease in some contexts and limited data available on newer conjugate vaccines (PCVs) regarding carriage efficacy in this population. Understanding the specific dynamics of susceptibility and clearance in PLHIV is critical for policy development, yet large-scale community trials are resource-intensive and slow.

Methodology
This study established and evaluated the first Controlled Human Infection Model (CHIM) for pneumococcal carriage specifically in PLHIV. The study was conducted in Blantyre, Malawi, between June 2023 and August 2024.

• Study Population: The trial enrolled 150 participants: 75 virally suppressed, clinically stable PLHIV (CD4 >350 cells/mm³, on ART for ≥2 years) and 75 HIV-uninfected controls. Participants were aged 25–45 years. Strict exclusion criteria applied, including recent respiratory infections, antibiotic use (except prophylactic cotrimoxazole for PLHIV), prior pneumococcal vaccination, and natural carriage of serotype 6B at baseline.
• Intervention: Participants received intranasal inoculation with live, penicillin-sensitive Streptococcus pneumoniae serotype 6B. Doses were escalated from 20,000 to 320,000 colony-forming units (CFU) per nostril. Participants who remained carriage-negative after the first inoculation underwent a second inoculation on day 14.
• Surveillance and Outcomes: Participants were monitored for 14 days post-inoculation (and up to day 28 for double-inoculated participants) via nasal wash samples collected on days 2, 7, and 13/14. Primary outcomes included the acquisition of experimental carriage (defined as culture-positive for serotype 6B), carriage density (area under the curve), and clearance rates. Safety was monitored via active and passive surveillance for adverse events. Acceptability was assessed via Likert scale questionnaires.
• Analysis: Statistical analyses compared carriage acquisition, density, and clearance between PLHIV and HIV-uninfected groups, adjusting for age and sex. Serum cotrimoxazole levels were measured in a subset of PLHIV to assess the impact of prophylaxis.

Key Results

• Safety and Acceptability: The model was safe and acceptable. No serious adverse events occurred. Mild adverse events were similar between groups (19% in PLHIV vs. 13% in controls; p=0.505). Over 90% of participants reported high acceptability, and 99% would recommend participation.
• Carriage Acquisition: Contrary to community observations, experimental carriage acquisition was significantly lower in PLHIV (21%; 16/75) compared to HIV-uninfected controls (36%; 27/75). The adjusted odds ratio (aOR) for acquisition in PLHIV was 0.39 (95% CI 0.16–0.91).
  • A dose-dependent relationship was observed in HIV-uninfected participants (p=0.004) but not statistically significant in PLHIV (p=0.113), though a trend was noted.
  • Among PLHIV without detectable serum cotrimoxazole, the carriage rate was 28% (8/29), compared to 3.4% (1/29) in those with detectable levels, suggesting cotrimoxazole partially explains the lower acquisition rate.
• Carriage Density: No statistically significant difference was found in the overall density of carriage (measured by AUC) between PLHIV and controls.
• Carriage Clearance: Clearance rates were lower in PLHIV. By day 14 post-inoculation, 59% of carriage-positive HIV-uninfected participants had cleared the bacteria, compared to only 36% of PLHIV. Survival analysis indicated a lower likelihood of clearance in PLHIV (Hazard Ratio 0.44; 95% CI 0.14–1.42), though the confidence interval crossed unity.

Significance and Claims
The paper claims to have successfully established a safe and ethical CHIM platform for studying pneumococcal carriage in PLHIV, a population previously excluded from such models. The primary significance of the findings lies in the unexpected discovery that, in carefully selected and virally suppressed PLHIV, the susceptibility to acquiring pneumococcal carriage is not higher than in HIV-uninfected adults.

The authors argue that the high carriage prevalence observed in PLHIV in the community is likely driven by prolonged carriage duration rather than increased susceptibility to initial acquisition. This distinction is supported by the observed slower clearance rates in PLHIV within the controlled model. The study suggests that factors such as cotrimoxazole prophylaxis and the strict selection criteria (which may have excluded individuals with high-risk sociodemographic factors like household contact with young children) influenced the results.

The paper concludes that this model provides a vital platform to investigate the mechanisms underlying impaired clearance in PLHIV and to evaluate interventions aimed at reducing the carriage burden. These findings have potential implications for pneumococcal vaccine policy in sub-Saharan Africa, shifting the focus from preventing acquisition to potentially addressing clearance mechanisms. The authors explicitly state that the study is not designed to evaluate vaccine efficacy but to elucidate the biological dynamics of carriage in this high-risk group.